A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients

ABSTRACT: Primary objectives: To evaluate the efficacy of cetuximab plus avelumab (in terms of Overall Survival - OS) as rechallenge strategy in RAS/BRAF wild type metastatic (according to liquid biopsy at baseline) colorectal cancer patients as compared to cetuximab alone. Primary endpoints: The primary endpoint for the trial is OS time, defined as the interval from enrollment to death for every cause.

DISEASE(S): Metastatic Colorectal Cancer,Pre-treated Ras/braf Wild Type Metastatic Colorectal Cancer Patients.,Pazienti Affetti Da Carcinoma Del Colon-retto Metastatico, Ras/braf Wild Type Precedentemente Trattati

PROVIDER: 2733983 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR